| Date | Time | Source | Headline | Symbol | Company |
| 05/08/2024 | 1:05PM | iHub Newswire | FeaturedElement79 Gold Corp Successfully Closes Maverick Springs Option Agreement | | |
| 03/07/2012 | 3:15AM | Zacks | Allos Narrows Loss - Analyst Blog | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/06/2012 | 4:08PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/06/2012 | 4:00PM | Business Wire | Allos Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/05/2012 | 4:11PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/01/2012 | 6:18PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/01/2012 | 6:17PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/01/2012 | 6:16PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/01/2012 | 6:15PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/01/2012 | 6:14PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/01/2012 | 6:14PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/01/2012 | 6:13PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/27/2012 | 5:48PM | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/27/2012 | 5:47PM | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (3/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/27/2012 | 5:45PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/27/2012 | 5:44PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/27/2012 | 5:44PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/27/2012 | 5:43PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/27/2012 | 5:42PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/27/2012 | 5:41PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/24/2012 | 6:13AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/23/2012 | 6:19PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/21/2012 | 8:00AM | Business Wire | Allos Therapeutics to Report Fourth Quarter and Full Year 2011 Results on March 6, 2012 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/14/2012 | 3:33PM | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/14/2012 | 12:04PM | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/14/2012 | 10:43AM | Edgar (US Regulatory) | Schedule 13G | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/10/2012 | 10:59AM | Edgar (US Regulatory) | Statement of Ownership (SC 13G) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/06/2012 | 12:46PM | Zacks | ALTH Seeks Review of Folotyn Verdict - Analyst Blog | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/31/2012 | 5:18PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/30/2012 | 8:30AM | Business Wire | Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at the European Medicines Agency | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |